Karyopharm Guarantees $3.7 Million to Executives, Replacing 2026 Bonus Plan
Distressed
Company Background
Karyopharm Therapeutics is a Newton, Massachusetts-based oncology company whose lead product, XPOVIO (selinexor), is a first-in-class oral XPO1 inhibitor approved in the U.S. for multiple myeloma. With a market cap of approximately $212.6 million, the company generated $146 million in total revenue for full-year 2025 but recorded a net loss of $196 million for the year, driven in part by a $62 million loss on debt extinguishment and $46 million in interest expense following a multi-part refinancing in October 2025. As of March 31, 2026, total liabilities stood at $397 million against total assets of $131 million, leaving the company with a stockholders' deficit of approximately $266 million.
The past year has been defined by liquidity management. In February 2026, Karyopharm signed a forbearance agreement with 100% of its term loan lenders and 100% of holders of both tranches of its 9.00% Convertible Senior Notes, deferring certain principal and interest payments and relaxing minimum liquidity covenants through October 2026 — conditioned on raising at least $25 million in fresh equity. In March 2026, the company satisfied that trigger through a $30 million private placement with RA Capital Management and approximately $19.8 million in at-the-market stock sales. That same month, Karyopharm voluntarily withdrew its FDA-accelerated approval for XPOVIO in diffuse large B-cell lymphoma after the agency determined the confirmatory trial could not feasibly be completed. Following those transactions, the company said its cash would fund operations into late Q3 2026.
Karyopharm now sits at what management describes as a critical clinical juncture. The Phase 3 SENTRY trial in myelofibrosis met one of its two co-primary endpoints in March 2026 — achieving statistically significant spleen volume reduction — while missing the symptom endpoint; the company is now engaging the FDA on a supplemental NDA filing plan. Enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial was completed in early 2026, with topline data expected in mid-2026. These two programs represent the company's primary path to meaningful revenue expansion.
What Was Disclosed
On July 13, 2026, the Board of Directors, acting on the recommendation of its Compensation Committee, adopted the "2026 Leadership Cash Retention Program" covering the company's named executive officers and CFO. The program provides lump-sum cash awards in the following amounts: Richard Paulson, President and CEO, $1,725,000; Dr. Reshma Rangwala, EVP, Chief Medical Officer and Head of Research, $725,000; Stuart Poulton, EVP and Chief Development Officer, $640,000; and Lori Macomber, EVP, CFO and Treasurer, $625,000 — a combined total of $3,715,000.
The filing states explicitly that the program "replaces previously guaranteed amounts under the Company's Annual Bonus Plan for 2026,